Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
NCT02110394 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 190
Last updated 2016-07-06
Summary
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia
Conditions
Interventions
- OTHER
-
bendamustine
Routine practice
- OTHER
-
rituximab
Routine practice
Sponsors & Collaborators
-
Astellas Pharma Europe B.V.
lead INDUSTRY
Principal Investigators
-
Clinical Study Manager · Astellas Pharma Europe B.V.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2015-08-31
- Completion
- 2015-08-31
Countries
- Russia
Study Locations
More Related Trials
-
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
NCT00864942 ·Status: COMPLETED ·Phase: PHASE1
-
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
NCT01832922 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
NCT01754870 ·Status: WITHDRAWN ·Phase: PHASE2
-
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
NCT00086203 ·Status: COMPLETED ·Phase: PHASE2
-
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
NCT06415708 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Mantle Cell Lymphoma Treatment by RiBVD
NCT01457144 ·Status: COMPLETED ·Phase: PHASE2
-
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT01234467 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
NCT01059630 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
NCT01029730 ·Status: COMPLETED ·Phase: PHASE2
-
Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia
NCT00274989 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
NCT00963534 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT00831597 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
NCT01661881 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
NCT05014100 ·Status: UNKNOWN ·Phase: PHASE2
-
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
NCT01737177 ·Status: COMPLETED ·Phase: PHASE2
-
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT04155840 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01776840 ·Status: COMPLETED ·Phase: PHASE3
-
Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
NCT02423837 ·Status: UNKNOWN ·Phase: PHASE3
-
Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL
NCT01990144 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
NCT00532129 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
NCT01429025 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT01197560 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
NCT01569295 ·Status: COMPLETED ·Phase: PHASE3